Showing results (231-240 of 364) with videos related to
Sort By:
Pageof 37
Journal of the American Academy of Dermatology|May 19, 2016
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled studyJon M Hanifin, Charles N Ellis, Ilona J Frieden, et al.Journal of the American Academy of Dermatology|December 6, 2022
Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trialLisa A Beck, Thomas Bieber, Stephan Weidinger, et al.The Journal of Allergy and Clinical Immunology. in Practice|October 4, 2017
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging TherapiesMark Boguniewicz, Andrew F Alexis, Lisa A Beck, et al.Journal of Drugs in Dermatology : JDD|February 23, 2019
Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in PracticeMark Lebwohl, Andrew F. Alexis, Lisa A. Beck, et al.Dermatology and Therapy|May 14, 2026
Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 TrialRichard G Langley, Lisa Arkin, Loretta Fiorillo, et al.Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|June 29, 2022
Breakthrough SARS-CoV-2 infections after COVID-19 immunizationJoshua Hirsh, Thwe Htay, Shubhang Bhalla, et al.Dermatology and Therapy|September 26, 2023
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic DermatitisMichael J Cork, Diamant Thaçi, Lawrence F Eichenfield, et al.Dermatology and Therapy|May 11, 2022
Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records DatasetLawrence F Eichenfield, April Armstrong, Emma Guttman-Yassky, et al.Journal of the American Academy of Dermatology|February 18, 2026
The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trialJonathan I Silverberg, Lawrence F Eichenfield, April W Armstrong, et al.Journal of the American Academy of Dermatology|August 12, 2015
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS studyIan Landells, Colleen Marano, Ming-Chun Hsu, et al.Pageof 37